Company Description
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders.
The company’s lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.
It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer’s disease and has completed phase 2 study for treatment of Huntington’s disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer.
The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses.
It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children’s Hospital of Philadelphia; Emory University; Huntington Study Group; H.
Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.
| Country | United States |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Maurice Zauderer |
Contact Details
Address: 1895 Mount Hope Avenue Rochester, New York 14620 United States | |
| Phone | 585 271 2700 |
| Website | vaccinex.com |
Stock Details
| Ticker Symbol | VCNX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001205922 |
| CUSIP Number | 918640103 |
| ISIN Number | US9186403013 |
| Employer ID | 16-1603202 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Maurice Zauderer Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Elizabeth E. Evans Ph.D. | Chief Operating Officer and Senior Vice President of Discovery and Translational Medicine |
| Dr. Ernest S. Smith Ph.D. | Senior Vice President of Research and Chief Scientific Officer |
| Jill Sanchez CPA | Chief Financial Officer |
| Dr. John E. Leonard Ph.D. | Senior Vice President of Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 25, 2024 | 424B3 | Prospectus |
| Oct 24, 2024 | EFFECT | Notice of Effectiveness |
| Oct 21, 2024 | UPLOAD | Filing |
| Oct 16, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 9, 2024 | 8-K | Current Report |
| Sep 27, 2024 | D | Notice of Exempt Offering of Securities |